Skip to main content
. 2022 Apr 4;36(6):e24362. doi: 10.1002/jcla.24362

FIGURE 4.

FIGURE 4

ACE2 promoter methylation levels in BRCA (UALCAN). (A) ACE2 promoter methylation levels in normal or BRCA samples. (B) ACE2 promoter methylation levels in normal individuals or stage 1, 2, 3, or 4 breast cancer patients. (C) ACE2 promoter methylation levels in normal individuals of any race or breast cancer patients of Caucasian, African‐American, or Asian race. (D) ACE2 promoter methylation levels in normal individuals or male or female BRCA patients. (E) ACE2 promoter methylation levels in normal individuals at any age or breast cancer patients aged 21–40, 41–60, 61–80, or 81–100 yrs. (F) ACE2 promoter methylation levels in normal individuals or nodal metastasis status N0, N1, N2, N3 BRCA patients. (G) ACE2 promoter methylation levels in normal individuals or patients with IDC, ILC, Mixed histology, Mucinous Carcinoma, Mucinous Carcinoma, Infiltrating Carcinoma NOS (INOS), Metaplastic Carcinoma, Medullary Carcinoma, or any other type of BRCA. (H) ACE2 promoter methylation levels in normal individuals or Luminal, HER2 positive, or TNBC patients. (I) ACE2 promoter methylation levels in normal individuals or Pre‐Menopause, Peri‐Menopause, or Post‐Menopause BRCA patients. (J) ACE2 promoter methylation levels in normal individuals or TP53‐Mutant or TP53‐NonMutant BRCA patients. (*p < 0.05, **p < 0.01, ***p < 0.001)